Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03322930 · ClinicalTrials.gov registry record

Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)

A clinical trial, sponsored by Retina Foundation of the Southwest.

Completed
Registry status
40
Enrollment target

NCT03322930 is a clinical trial that has completed, run by Retina Foundation of the Southwest. The registered enrollment target is 40 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03322930 has completed, sponsored by Retina Foundation of the Southwest.

COMPLETED
Registry status
40 participants
Enrollment target

Study Summary

A new fundus-guided microperimeter (MP-3S) has been developed by Nidek, Inc. to track the fundus of the patient and present stimuli in specific anatomically-defined locations. Furthermore, this tracking means that exactly the same locations can be tested on subsequent (follow-up) visits. The investigators will use a method called two-color perimetry to map rod and cone sensitivity on this device. With this technique, the sensitivity difference (blue-red) to chromatic test stimuli can be used to determine whether rods, cones or both photoreceptor systems mediate the threshold at a given location in the macula.

Interventions

  • DIAGNOSTIC_TEST Rod sensitivity

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2017-10-01
Est. Completion 2019-03-01

Sponsor

Retina Foundation of the Southwest

11 total trials

What the Registry Record Tells You About NCT03322930

The ClinicalTrials.gov registry entry for NCT03322930 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Retina Foundation of the Southwest, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Rod sensitivity is the first listed.

NCT03322930 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03322930 about?

NCT03322930 is a clinical study titled "Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)". A new fundus-guided microperimeter (MP-3S) has been developed by Nidek, Inc. to track the fundus of the patient and present stimuli in specific anatomically-defined locations. Furthermore, this tracking means that exactly the same locations can be tested on subsequent (follow-up) visits. The investi...

What is the current status of trial NCT03322930?

This trial is currently completed. The enrollment target is 40 participants. The study started on 2017-10-01. Estimated completion is 2019-03-01.

What interventions are being tested in trial NCT03322930?

The interventions under investigation include: Rod sensitivity (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03322930?

This trial is sponsored by Retina Foundation of the Southwest, which has 11 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.